Arnolds S,Rave K,Hovelmann U,et al.Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. Experimental and Clinical Endocrinology . 2010Amolds S; Rave K; Hovelmann U;.Insulin glulisine has a faster onset of action compared with insulin aspart in ...
These structural modifications decrease hexamer formation, stabilize insulin glulisine monomers and increase the rate of absorption and onset of action compared to human insulin. 药物别名 Insulin glulisine;Insulin Glulisine (recombinant DNA origin);Insulin glulisine recombinant;Insulina glulisina 治疗...
Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab 2007; 9: 746-753.Heise T, Nosek L, Spitzer H, Heinemann L, Niemöller E, Frick AD, Becker RHA (2007) Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes ...
Insulin glulisine is a rapid-acting human insulin analogue that has a faster onset of action and shorter duration of action than regular human insulin (RHI) in patients with type 1 or 2 diabetes mellitus and is efficacious in controlling prandial blood glucose levels in these patients. In ...
RESULTS/CONCLUSION: Insulin glulisine offers a more rapid onset of action and shorter duration of action compared with regular human insulin. These characteristics result in an action profile that closely mimics the normal postmeal endogenous insulin response, thus fulfilling the prandial insulin ...
Insulin glulisine (Apidra, Sanofi-Aventis), a new and recently approved rapid-acting insulin analogue, mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin, but has a rapid onset, peak effect at 1h, and a shorter duration of action (approximately 4 h). Its rapid...
Subcutaneous administration of insulin glulisine has a faster subcutaneous absorption, a more rapid onset of activity, and a shorter duration of action than regular human insulin. These properties of insulin glulisine allow it to be administered shortly before or soon after mea...
Insulin glulisine (Apidra, Sanofi-Aventis), a new and recently approved rapid-acting insulin analogue, mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin, but has a rapid onset, peak effect at 1h, and a shorter duration of action (approximately 4 h). Its rapid...
Subcutaneous administration of insulin glulisine has a faster subcutaneous absorption, a more rapid onset of activity, and a shorter duration of action than regular human insulin. These properties of insulin glulisine allow it to be administered shortly before or soon after meals by subcutaneous ...
Rapid-acting insulin analogs (RAIAs) have a more rapid onset, a shorter duration of action and better match the physiologic insulin needs of people with T1D compared with regular human insulin (RHI). Switching from RHI to RAIAs may require changes in basal and bolus insulin doses. MEDLINE ...